Skip to content

SABS - SAB Biotherapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchS

SAB Biotherapeutics Inc

SABS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

S

SABSSAB Biotherapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $5.15
52-wk low: $1.85
Prev close: $3.57
Mkt cap: $343.9M
P/E: 15.8x
Beta: 0.53

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$45.2M

BA
Balyasny
Dmitry Balyasny · Q2 2026 13F
$14.7M
position
MI
Millennium
Israel Englander · Q2 2026 13F

Earnings

Reported Aug 6, 2026

Earnings came in 3.4% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

Fairly priced and running thin margins.

Net margin: 0.0%
P/E: 15.75
Market cap: $344M

Valuation

P/S2.96
P/B1.60

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: SABS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $343.93M
Beta: 0.53

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/S

3.0x

P/B

1.6x

Profit margin

+0.0%

Op margin

+0.0%

ROE

-11.3%

$10.7M

position

EP

ExodusPoint

Michael Gelband · Q1 2026 13F

$2.9M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for SABS

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.28+3.4%

-$0.29 expected

Next report

What the street expects next

-11.3%

ROA-33.5%

Growth

Beta0.53